Skip to content

Lucid Diagnostics LUCD Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Castle Biosciences logo
Castle BiosciencesCSTL
Guardant Health logo
Guardant HealthGH
Biodesix, Inc. logo
Biodesix, Inc.BDSX
Insight Molecular Diagnostics Inc. Common Stock logo
Insight Molecular Diagnostics Inc. Common StockIMDX
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
Personalis, Inc. logo
Personalis, Inc.PSNL

Other financials

Income statement

See full
Revenue$1.3M+51.7%
Gross profit-$369.0K+49.0%
Operating income-$12.1M+3.0%
Net income-$13.9M+48.3%
EPS (diluted)-$0.10+60.0%

Balance sheet

See full
Cash & equivalents$27.9M+10.6%
Total debt$1.6M-35.1%
Total equity$4.0M+174%
Total assets$34.1M+3.9%

Cash flow

See full
Operating cash flow-$12.1M+2.9%
CapEx$215.0K+131%
Free cash flow-$12.3M+1.9%

Valuation

See full
Market cap$204.13M+58.5%
Enterprise value$177.85M+78.0%
P/S39.8×+10.2×

Profitability

See full
Gross margin-66.8%
Operating margin-959.6%-133pp
Net margin-876.7%-254pp
FCF margin-1,099.6%

Returns & leverage

See full
Return on equity-710.6%
Debt / equity0.4×
Current ratio1.1×+0.3×

Where this comes from

Reported directly by Lucid Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lucid Diagnostics's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lucid Diagnostics's deferred tax assets and other non-current assets?
Lucid Diagnostics (LUCD) reported deferred tax assets and other non-current assets of $10K in Q1 2026.
How has Lucid Diagnostics's deferred tax assets and other non-current assets changed year-over-year?
Lucid Diagnostics's deferred tax assets and other non-current assets decreased by 99.1% year-over-year, from $1.13M to $10K.
What is the long-term trend for Lucid Diagnostics's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Lucid Diagnostics's deferred tax assets and other non-current assets has grown at a -42.6% compound annual growth rate (CAGR), from $755K to $47K.